US Bancorp DE Acquires 368 Shares of LeMaitre Vascular, Inc. $LMAT

US Bancorp DE raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 36.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,390 shares of the medical instruments supplier’s stock after buying an additional 368 shares during the period. US Bancorp DE’s holdings in LeMaitre Vascular were worth $117,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Northern Trust Corp increased its stake in LeMaitre Vascular by 5.1% during the 4th quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier’s stock worth $30,205,000 after acquiring an additional 15,843 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of LeMaitre Vascular by 9.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier’s stock valued at $23,921,000 after purchasing an additional 25,680 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of LeMaitre Vascular by 0.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 284,779 shares of the medical instruments supplier’s stock valued at $26,240,000 after acquiring an additional 1,680 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of LeMaitre Vascular by 50.5% during the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier’s stock valued at $16,124,000 after acquiring an additional 58,720 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in LeMaitre Vascular during the 4th quarter worth about $14,900,000. Institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $95.91 on Monday. LeMaitre Vascular, Inc. has a twelve month low of $71.42 and a twelve month high of $109.58. The company has a quick ratio of 11.74, a current ratio of 13.96 and a debt-to-equity ratio of 0.46. The stock’s 50 day moving average price is $84.56 and its 200-day moving average price is $86.34. The company has a market capitalization of $2.17 billion, a PE ratio of 46.56, a PEG ratio of 2.47 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The business had revenue of $63.15 million for the quarter, compared to analysts’ expectations of $62.48 million. During the same quarter in the previous year, the firm posted $0.52 EPS. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. On average, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be issued a $0.20 dividend. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 annualized dividend and a dividend yield of 0.8%. LeMaitre Vascular’s dividend payout ratio is presently 38.83%.

Insider Activity

In other news, CEO George W. Lemaitre sold 100,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $93.51, for a total value of $9,351,000.00. Following the transaction, the chief executive officer owned 1,727,003 shares of the company’s stock, valued at approximately $161,492,050.53. This represents a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John A. Roush sold 6,561 shares of the stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the transaction, the director directly owned 2,916 shares in the company, valued at approximately $269,875.80. This represents a 69.23% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 125,214 shares of company stock worth $11,654,560. Company insiders own 9.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Barrington Research raised LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $95.00 price objective for the company in a research report on Wednesday, August 6th. Cantor Fitzgerald lifted their price target on LeMaitre Vascular from $92.00 to $95.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $98.00.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.